Anti-mouse CD52antibody ameliorates colitis through suppressing Th1/17 mediated inflammation and promoting regulatory T cell response in interleukin-10 deficient mice / 中华内科杂志

In this study, we evaluated the therapeutic effects and possible mechanisms of anti-CD52 treatment on interleukin-10 (IL-10) deficient mice. Anti-mouse CD52 monoclonal antibody was administrated to C3H. IL-10-/-mice. The disease activity index, histological grading of colitis, serum Th1/17 related cytokines, percentage of CD25+Foxp3+T cells in colon as well as CD25, Foxp3 gene expression were measured. Our data suggested that anti-CD52 treatment inhibited colitis in C3H.IL-10-/-mice and it might be related to the suppression of Th1/17 related inflammation and the promotion of regulatory T cell differentiation.